Early administration of remdesivir may reduce mortality in hospitalized COVID-19 patients : A propensity score matched analysis.

ABSTRACT:

Background

Remdesivir is the only antiviral agent approved for the treatment of hospitalized coronavirus disease 2019 (COVID-19) patients requiring supplemental oxygen. Studies show conflicting results regarding its effect on mortality.

Methods

In this single center observational study, we included adult hospitalized COVID-19 patients. Patients who were treated with remdesivir were compared to controls. Remdesivir was administered for 5 days. To adjust for any imbalances in our cohort, a propensity score matched analysis was performed. The aim of our study was to analyze the effect of remdesivir on in-hospital mortality and length of stay (LOS).

Results

After propensity score matching, 350 patients (175 remdesivir, 175 controls) were included in our analysis. Overall,

SUBMITTER: Karolyi M 

PROVIDER: S-EPMC9610353 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature